Why the study?
Does blood collection into CTAD plus iloprost reduce artefactual in vitro release of sP-selectin compared to standard anticoagulants in volunteers?
Does blood collection into CTAD plus iloprost reduce artefactual in vitro release of sP-selectin compared to standard anticoagulants in volunteers?
Using CTAD plus iloprost for blood collection prevents in vitro platelet activation, providing a more accurate measurement of circulating sP-selectin levels.
Answers are grounded in this paper and cite their sources.
Standard collections may overestimate circulating sP-selectin; supports CTAD-iloprost for accurate research assays but requires clinical validation.
P-selectin is stored preformed in the alpha-granules of platelets. Previous studies show ss-thromboglobulin, also stored in alpha-granules can be readily released from platelets during the processing of whole blood. This artefactual release was rectified by using combination of various anti-platelet and anticoagulant compounds placed in the collecting tube. We investigated the levels of sP-selectin from 40 volunteers, comparing two anticoagulants, tri-sodium citrate, CTAD (a mixture of sodium citrate and citric acid, theophylline, adenosine and dipyridamole) plus iloprost and serum. Iloprost, a stable prostacyclin analogue, is a potent anti-platelet agent. We found significantly lower levels of sP-selectin (P< 0.0001, paired t-test) measured from blood collected into CTAD and iloprost compared to levels measured from either citrated plasma or serum. We suggest that plasma levels obtained from the blood collected into a CTAD tube containing iloprost are likely to more accurately reflect the true levels of circulating sP-selectin than those obtained when test-tube activation of platelets is allowed to continue in vitro.
No takes yet. Share an insight, caveat, or question.
Kirk et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: